Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024

Ad - Bora Pharmaceuticals

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,  announced a revised supply agreement with the Government of Canada for up to 105 million doses of Moderna’s COVID-19 vaccine and its booster vaccine candidate, if authorized, for delivery through 2024. The agreement provides for 20 million doses each year in 2022 and 2023, with an option for an additional 15 million doses each year. For 2024, the agreement provides an option for up to 35 million doses.

“We thank the Government of Canada for their support in this supply agreement for our mRNA COVID-19 vaccine and booster candidate, if approved,” said Stéphane Bancel, Moderna’s Chief Executive Officer. “This agreement reflects the efforts of the Canadian government to address the ongoing pandemic and builds on our existing collaboration to protect Canadian citizens.”

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 23 development programs are underway across these therapeutic areas, with 15 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years.

Advertisement